Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- FDA authorizes investigational new drug application for recombinant human C1 inhibitor in kidney transplantation
- Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that the US Food and Drug Administration FDA has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection AMR in kidney transplantation. Dr. Hans Sollinger of the University of...
- Research articles 2008-09-03
- PHARMING RECIEVES ORPHAN DRUG DESIGNATIONS FOR RHC1INH FROM US FDA
- Leiden, The Netherlands, June 14, 2006. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) announced today it has received orphan drug designations for recombinant human C1 inhibitor (rhC1INH) from the Food and Drug Administration FDA. The Company has obtained...
- Research articles 2006-06-14
- PHARMING RECEIVES FAST TRACK DESIGNATION FROM US FDA FOR RECOMBINANT HUMAN C1 INHIBITOR
- Leiden, The Netherlands, July 28, 2006. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) announced today that it has received a Fast Track designation on recombinant human C1 inhibitor (rhC1INH) for the treatment of hereditary angioedema HAE from the US Food and Drug...
- Research articles 2006-07-28
- PHARMING RECEIVES ORPHAN DRUG DESIGNATION FOR RECOMBINANT FIBRINOGEN FROM FDA
- PHARMACEUTICAL DEVELOPMENT For FiBRINOGEN DEFICIENCIEs Initiated
- Research articles 2007-10-11
- PHARMING RECIEVES ORPHAN PRODUCT GRANT FROM US FDA FOR RHUCIN(R)
- Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) announced today that it has received a grant from the US FDA's Office of Orphan Products Development OPD for the clinical development...
- Research articles 2006-10-06
- << Previous
- page 1 of 1
- Next >>
